CLSI H56
Body Fluid Analysis for Cellular Composition
This CLSI document provides recommendations for standardizing body fluid collection, transport, and cellular analysis. It offers guidance on numeration, identification, and qualitative and quantitative assessment to support accurate and reliable results.
{{FormatPrice(currentPrice)}}
Free
{{FormatPrice(nonMemberPrice)}} List PriceClinical and Laboratory Standards Institute document H56-A—Body Fluid Analysis for Cellular Composition; Approved Guideline provides recommendations for standardizing the collection and transport of body fluids, numeration and identification of cellular components, and guidance for qualitative and quantitative assessment of body fluid.
The intended purpose of this guideline is to explain how to collect, process, examine, store, and report results for body fluid specimens for the characterization of inflammatory, infectious, neoplastic, and immune alterations. It will also discuss preanalytical, analytical, and postanalytical variables related to body fluid cellular analyses. For the purpose of this document, the following body fluids will be discussed: cerebrospinal, serous (pleural, peritoneal, pericardial) and related fluids (i.e., peritoneal dialysate, peritoneal lavage), bronchoalveolar, and synovial fluids.
This guideline describes manual and automated methods to enumerate cellular components and to identify normal and abnormal elements. It also addresses additional studies that may be used for body fluid testing in the routine clinical laboratory.
This document is intended for medical technologists, pathologists, microbiologists, cytologists, nurses, and other healthcare professionals responsible for the collection and transport of body fluid specimens to the clinical laboratory, as well as the processing, testing, and reporting of results. It is also intended for manufacturers of products or instruments used for body fluid testing.
This document is available in electronic format only.
This archived document is no longer being reviewed through the CLSI Consensus Document Development Process. However, this document is technically valid and because of its value to the laboratory community, it is being retained in CLSI’s library.
The U.S. Food and Drug Administration (FDA) has evaluated and recognized this approved-level consensus standard for use in satisfying a regulatory requirement.
A CLSI-IFCC joint project.
Clinical and Laboratory Standards Institute document H56-A—Body Fluid Analysis for Cellular Composition; Approved Guideline provides recommendations for standardizing the collection and transport of body fluids, numeration and identification of cellular components, and guidance for qualitative and quantitative assessment of body fluid.
The intended purpose of this guideline is to explain how to collect, process, examine, store, and report results for body fluid specimens for the characterization of inflammatory, infectious, neoplastic, and immune alterations. It will also discuss preanalytical, analytical, and postanalytical variables related to body fluid cellular analyses. For the purpose of this document, the following body fluids will be discussed: cerebrospinal, serous (pleural, peritoneal, pericardial) and related fluids (i.e., peritoneal dialysate, peritoneal lavage), bronchoalveolar, and synovial fluids.
This guideline describes manual and automated methods to enumerate cellular components and to identify normal and abnormal elements. It also addresses additional studies that may be used for body fluid testing in the routine clinical laboratory.
This document is intended for medical technologists, pathologists, microbiologists, cytologists, nurses, and other healthcare professionals responsible for the collection and transport of body fluid specimens to the clinical laboratory, as well as the processing, testing, and reporting of results. It is also intended for manufacturers of products or instruments used for body fluid testing.
This document is available in electronic format only.
This archived document is no longer being reviewed through the CLSI Consensus Document Development Process. However, this document is technically valid and because of its value to the laboratory community, it is being retained in CLSI’s library.
The U.S. Food and Drug Administration (FDA) has evaluated and recognized this approved-level consensus standard for use in satisfying a regulatory requirement.
A CLSI-IFCC joint project.